• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Supernus Pharm (NQ: SUPN )

    36.18 -1.59 (-4.21%)
    Streaming Delayed Price Updated: 1:17 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Supernus Pharm

    < Previous 1 2 3 Next >
    ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
    Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million. 
    Via Benzinga
    This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
    Via Benzinga
    Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals.
    In a market where value is scarce, SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) offers a refreshing opportunity with its solid fundamentals. 
    Via Chartmill
    If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
    Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. 
    Via InvestorPlace
    Recap: Supernus Pharmaceuticals Q4 Earnings
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
    Via Benzinga
    Supernus Pharmaceuticals: Q3 Earnings Insights
    Via Benzinga
    Supernus Pharmaceuticals's Earnings: A Preview
    Via Benzinga
    NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
    Via Chartmill
    Trading SMID Biotech Stocks In A Volatile Market
    Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
    Via Talk Markets
    Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents.
    SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) stands out as a stock that provides good value for the fundamentals it showcases. 
    Via Chartmill
    SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
    SUPN stock results show that Supernus Pharmaceuticals missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
    Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product... 
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Biotechnology And Healthcare, A Bit Of A Lull
    Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors. 
    Via Talk Markets
    Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
    The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. 
    Via InvestorPlace
    Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
    Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... 
    Via Benzinga
    Exposures Product Safety
    Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
    Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way. 
    Via The Motley Fool
    Earnings Scheduled For November 8, 2023
    Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
    Via Benzinga
    Market Mixes It Up With A Broad Rally
    Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
    Via Talk Markets
    Stocks That Hit 52-Week Lows On Monday
      On Monday, 369 companies set new 52-week lows. 
    Via Benzinga
    Time To Play Small Cap Life Science Stocks
    The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
    Via Talk Markets
    Stocks That Hit 52-Week Lows On Thursday
      During the session on Thursday, 461 stocks hit new 52-week lows. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
      During Tuesday's session, 275 companies made new 52-week lows. 
    Via Benzinga
    Something Happened In Biotech Last Week
    Biotech stocks were more constructive last week with some sharp moves up. 
    Via Talk Markets
    Stocks That Hit 52-Week Lows On Friday
      Friday's session saw 169 companies set new 52-week lows. 
    Via Benzinga
    When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
    A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
    Via Talk Markets
    Earnings Scheduled For May 9, 2023
    Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
    Via Benzinga
    Earnings Scheduled For February 28, 2023
    Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
    Via Benzinga
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.